07:15-08:15 |
Industry sponsored satellite symposia 3a, 3b & 3c
|
08:30-10:30 |
Scientific session 4: The future of IBD diagnosis and disease prediction Iris Dotan, Petah Tikva, Israel Jonas Halfvarson, Örebrö, Sweden
|
|
08:30-08:50 |
ECCO-ESGAR Guidelines: Present and future of diagnostic techniques for IBD Jaap Stoker, Amsterdam, The Netherlands Christian Maaser, Lueneburg, Germany |
|
08:50-09:00 |
OP009: A combination of clinical, serological and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study. H. Sarter1, 2, G. Savoye3, D. Turck2, 4, F. Vasseur5, G. Marot6, 7, B. Pariente2, 8, S. Singh9, J.F. Colombel10, C. Gower-Rousseau1, 2, M. Fumery11 1. Lille Hospital and University, Public Health, Epidemiology and Economic Health, Epimad registry, Regional house of clinical research, Lille, France 2. Lille University, Lille Inflammation Research International Center LIRIC-UMR 995 Inserm, Lille, France 3. Rouen Hospital and University, Gastroenterology Unit, Epimad registry, Rouen, France 4. Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille, France 5. Lille University and Hospital, Biostatistics Unit, EA 2694, Lille, France 6. Lille University and Hospital, EA 2694 - Santé publique : épidémiologie et qualité des soins, Lille, France 7. Inria Lille Nord Europe, Modal, Lille, France 8. Gastroenterology Unit, Epimad registry, Lille Hospital and University, Lille, France 9. Prometheus Laboratories Inc., San Diego, United States 10. Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States 11. Amiens Hospital and University, Gastroenterology Unit, EPIMAD Registry, Amiens, France |
|
09:00-09:10 |
OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative Colitis I. Al Bakir1, 2, K. Curtius1, A.-M. Baker1, T.S.O. Clarke1, M. Moorghen3, M. Jansen4, M. Rodriguez-Justo4, S. Leedham5, T. Graham*1, A. Hart*2 1. Queen Mary University of London, Barts Cancer Institute, London, United Kingdom 2. St. Mark's Hospital, Inflammatory Bowel Disease Unit, Harrow, United Kingdom 3. St. Mark's Hospital, Pathology Department, Harrow, United Kingdom 4. University College London Hospital, Pathology Department, London, United Kingdom 5. Henry Wellcome Building of Genomic Medicine, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom |
|
09:10-09:20 |
OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects R. Barbieri1, W. Uniken Venema1, A. Vich Vila1, Y. Li1, L. Franke1, F. van Dijk1, N. De Klein1, M. Swertz1, S. Sanna1, M.D. Voskuil1, M. Rivas2, R. Xavier2, M. Daly2, G. Dijkstra1, E.A. Festen1, R.K. Weersma1 1. UMCG, Groningen, Netherlands 2. The Broad Institute of MIT and Harvard, Cambridge, United States |
|
09:20-09:40 |
Molecular endoscopy for IBD Raja Atreya, Erlangen, Germany |
|
09:40-09:50 |
OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s Disease patients H. Schmitt1, U. Billmeier1, W. Dieterich1, T. Rath1, S. Sonnewald2, S. Reid2, S. Hirschmann1, K. Hildner1, M.J. Waldner1, J. Mudter3, A. Hartmann4, R. Grützmann5, C. Neufert1, T. Münster6, M.F. Neurath1, R. Atreya1 1. Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany 2. Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany 3. Sana Kliniken Ostholstein, Eutin, Germany 4. Friedrich-Alexander-University Erlangen-Nürnberg, Deparment of Pathology, Erlangen, Germany 5. Friedrich-Alexander-University Erlangen-Nürnberg, Department of Surgery, Erlangen, Germany 6. Friedrich-Alexander-University Erlangen-Nürnberg, Department of Anesthesiology, Erlangen, Germany |
|
09:50-10:00 |
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease A. Sazonovs1, N.A. Kennedy2, C. Bewshea2, L. Moutsianas1, G.J. Walker2, K. De Lange1, J. Goodhand2, C. Anderson1, J. Barrett1, PANTS Investigator Consortium, T. Ahmad2 1. Wellcome Trust Sanger Institute, Hinxton, United Kingdom 2. University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom |
|
10:00-10:10 |
OP014:Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome A. Vich Vila1, F. Imhann1, V. Collij1, S.A. Jankipersadsing1, T. Gurry2, Z. Mujagic3, A. Kurilshikov1, M.J. Bonder1, J. Xiaofang2, E. Tigchelaar1, J. Dekens1, V. Peters1, M.D. Voskuil1, M.C. Visschedijk1, F. Eleonora A.M.1, G. Dijkstra1, A.A. Masclee3, M.H. Hofker1, R. Xavier4, E.J. Alm2, J. Fu1, C. Wijmenga1, D.M. Jonkers3, A. Zhernakova1, R.K. Weersma1 1. University Medical Center Groningen, Groningen, Netherlands 2. Massachusetts Institute of Technology, Boston, United States 3. Maastricht University Medical Center (MUMC), Maastricht, Netherlands 4. Broad Institute, Boston, United States |
|
10:10-10:30 |
Integration of "omics" and potential for clinical practice Claudio Fiocchi, Cleveland, United States |
10:30-11:00 |
Coffee Break |
11:00-12:30 |
Scientific session 5: New opportunities for IBD care and research Dominik Bettenworth, Münster, Germany James Lindsay, London, United Kingdom
|
|
11:00-11:20 |
Remote monitoring Daniel Baumgart, Berlin, Germany
|
|
11:20-11:40 |
Point of care tests Ann Gils, Leuven, Belgium
|
|
11:40-12:00 |
Web-based registries Pascal Juillerat, Bern, Switzerland |
|
12:00-12:10 |
OP015:Biomarker correlation with endoscopic outcomes in patients with Crohn’s Disease: Data from CALM W. Reinisch1, R. Panaccione2, P. Bossuyt3, F. Baert4, A. Armuzzi5, S. Travis6, S. Danese7, W.J. Sandborn8, G. D'Haens9, S. Berg10, J.-F. Maa11, J. Petersson11, E. Neimark11, A.M. Robinson11, J.-F. Colombel12 1. Medical University of Vienna, Vienna, Austria 2. University of Calgary, Calgary, Canada 3. Imelda General Hospital, Bonheiden, Belgium 4. AZ Delta Roeselare-Menen, Menen, Belgium 5. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy 6. Oxford University Hospitals, Oxford, United Kingdom 7. Istituto Clinico Humanitas, Milan, Italy 8. University of California San Diego, La Jolla, United States 9. Academic Medical Center, Amsterdam, Netherlands 10. AbbVie AB, Solna, Sweden 11. AbbVie Inc., North Chicago, United States 12. Icahn School of Medicine at Mount Sinai, New York, United States |
|
12:10-12:30 |
Can the patient become an investigator? Germari Bianchi, Milan, Italy |
12:30-13:30 |
Break |
12:30-13:30 |
Guided poster session |
12:40-13:20
|
Industry sponsored lunchtime satellite symposia LS1,LS2,LS3,LS4
|
13:30-15:00 |
Scientific session 6: Best perioperative management of IBD Yves Panis, Clichy, France Walter Reinisch, Vienna, Austria |
|
13:30-13:50 |
Get your patient fit for surgery Paulo Kotze, Curitiba, Brazil; Calgary, Canada Peter Irving, London, United Kingdom
|
|
13:50-14:00 |
OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014 D. Kalman1, C. Nordenvall2, A. Hallqvist Everhov3, J.F. Ludvigsson4, M.C. Sachs5, A. Ekbom6, O. Olén7, P. Myrelid1 1. Division of surgery, Department of Clinical and Experimental Medicine, Faulty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden 2. Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden 3. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden 4. Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden 5. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 6. Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden 7. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden |
|
14:00-14:20 |
Enhanced postoperative recovery pathways Gionata Fiorino, Milan, Italy Antonino Spinelli, Milan, Italy
|
|
14:20-14:30 |
OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database G. Pellino1, 2, K. Sahnan2, 3, M. Penna3, 4, S. Adegbola2, 3, P. Chandrasinghe2, 3, 5, A. Spinelli6, 7, R. Hompes4, J. Warusavitarne2, 3, on behalf of the International TaTME Registry Collaborative. 1. Università della Campania, Unit of Colorectal Surgery, Naples, Italy 2. St Mark's Hospital, Fistula Research Unit, London, United Kingdom 3. Imperial College, Department of Surgery and Cancer, London, United Kingdom 4. Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, United Kingdom 5. Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka 6. Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy 7. Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy |
|
14:30-14:40 |
OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling C. Mascaraque1, S. Elangovan2, L. Petti1, A. Piontini2, C. Correale1, V. Arena3, B. Romano1, F. Ungaro2, V. Garlatti2, S. D'Alessio2, G. Fiorino1, A. Spinelli2, 4, S. Danese1, 2, S. Vetrano2 1. Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy 2. Humanitas University, Department of Biomedical Sciences, Rozzano, Italy 3. Catholic University of Rome, Institute of Pathology, Rome, Italy 4. Humanitas Reseach Institute, Colon and Rectal Surgery, Rozzano, Italy |
|
14:40-15:00 |
Preventive strategy after resection surgery in CD Pierre Michetti, Lausanne, Switzerland
|
15:00-15:30 |
Coffee break |
EITHER: |
15:30-16:10 |
Scientific session 7: ECCO Fellowships and Grants Gerhard Rogler, Zurich, Switzerland Dino Tarabar, Belgrade, Serbia |
|
15:30-15:37 |
Outcomes from the ECCO-IOIBD Fellowship 2016: The interleukin-1 pathway as a putative new target in paediatric Inflammatory Bowel Disease Sharon Veenbergen, Rotterdam, The Netherlands |
|
15:37-15:44 |
Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning Aria Zand, Los Angeles, United States |
|
15:44-15:50 |
Announcement of ECCO Fellowships & Grants 2018
|
|
15:50-16:00 |
OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study) S. Paramsothy1, 2, M. Kamm3, 4, S. Nielsen1, N. Deshpande1, J. Faith2, J. Clemente2, R. Paramsothy5, A. Walsh6, J. van den Bogaerde7, D. Samuel8, R. Leong8, S. Connor5, W. Ng5, E. Lin9, M. Wilkins1, J.-F. Colombel2, T. Borody9, H. Mitchell1, N. Kaakoush1 1. University of New South Wales, Sydney, Australia 2. Icahn School of Medicine at Mount Sinai, New York, United States 3. St Vincent's Hospital, Melbourne, Australia 4. University of Melbourne, Melbourne, Australia 5. Liverpool Hospital, Sydney, Australia 6. St Vincent's Hospital, Sydney, Australia 7. Nambour General Hospital, Nambour, Australia 8. Bankstown-Lidcombe Hospital, Sydney, Australia 9. Centre for Digestive Diseases, Sydney, Australia |
|
16:00-16:10 |
OP020: The clinical determinants affect gut microbial profile of Inflammatory Bowel Disease patients P. Juillerat1, B. Yilmaz2, R. Wiest1, 2, G. Rogler3, A.J. Macpherson1 1. Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland 2. University of Bern, Department of Biomedical Research, Bern, Switzerland 3. University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland |
16:10-17:10 |
Scientific session 8: IBD Horizons Filip Baert, Roeselare, Belgium Gerassimos Mantzaris, Athens, Greece |
|
16:10-16:20 |
OP021: Autologous haematopoietic stem cell transplantation for Crohn’s Disease: A retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party C. Brierley1, C. Castilla-Llorente2, M. Labopin3, M. Badoglio3, M. Rovira4, E. Ricart5, D. Dierickx6, S. Vermeire7, P. Hasselblatt8, J. Finke9, F. Onida10, A. Cassinotti11, J. Satsangi12, M. Kazmi13, A. López-Sanromán14, D. Farge15, S. Travis16, C. Hawkey17, J. Snowden18 1. Oxford University Hospitals, Department of Haematology, Oxford, United Kingdom 2. Département d’Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France 3. Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France 4. Hospital Clínic of Barcelona, Haematology Department, Barcelona, Spain 5. Hospital Clínic of Barcelona, Gastroenterology Department, Barcelona, Spain 6. University Hospitals Leuven, Department of Haematology, Leuven, Belgium 7. University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium 8. Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany 9. University of Freiburg, Department of Gastroenterology, Freiburg, Germany 10. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Spain 11. Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy 12. Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom 13. Guy's and St Thomas' NHS Foundation Trust and King's College Hospital, Department of Haematology, London, United Kingdom 14. Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain 15. AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France (site constitutif), Filière FAI2R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France 16. Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, United Kingdom 17. Queen’s Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, United Kingdom 18. Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, United Kingdom
|
|
16:20-16:30 |
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study S. Schreiber1, L. Peyrin-Biroulet2, B. Boland3, P.D. Higgins4, A. Armuzzi5, J. Terdiman6, W. Zhou7, G. Alperovich8, F. Cataldi7, S. Goteti7, A.P. Lacerda7 1. University Hospital Schleswig-Holstein, Kiel, Germany 2. University of Lorraine, Nancy, France 3. University of California, San Diego, San Diego, United States 4. University of Michigan, Ann Arbor, United States 5. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy 6. University of California, San Francisco, Medical Center at Parnassus, San Francisco, United States 7. AbbVie Inc., North Chicago, United States 8. AbbVie Spain S.L.U., Madrid, Spain |
|
16:30-16:40 |
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn's Disease (CD) S. Danese1, B. Feagan2, W. Sandborn3, J.-F. Colombel4, S. Vermeire5, S. Jones6, K. Brennan6, J. Bornstein7 1. Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy 2. University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada 3. University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, United States 4. Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, NY, United States 5. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 6. Europe Development Centre, Takeda R&D, London, United Kingdom 7. Takeda Pharmaceuticals International Co., Cambridge, MA, United States |
|
16:40-16:50 |
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study G.R. D´Haens1, W. Reinisch2, S.D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D.I. Park9, X. Hébuterne10, F. Cataldi11, A. Banerjee12, K. Gorelick13, W.J. Sandborn14 1. Academic Medical Centre, Amsterdam, Netherlands 2. Medical University of Vienna, Vienna, Austria 3. University of Washington, Seattle, United States 4. Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia 5. University Hospital CHU of Liège, Liège, Belgium 6. Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland 7. Universitatsklinikum Ulm, Ulm, Germany 8. University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany 9. Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea 10. Université de Nice Sophia Antipolis, Hôpital de l'Archet, Nice, France 11. Shire, Lexington, United States 12. Pfizer, Cambridge, United States 13. Zymo Consulting Group, Newtown Square, United States 14. University of California San Diego, La Jolla, United States |
|
16:50-17:00 |
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis M. Bohm1, S. V Sagi1, M. Fischer1, S. Kadire1, G. Tran1, M. Rahal1, S. Aniwan2, J. Meserve3, A. Weiss4, G. Kochhar5, P. Shashi5, D. Faleck6, A. Winters6, S. Chablaney6, J.L. Koliani-Pace7, B. Boland3, S. Singh3, R. Hirten6, E. Shmidt6, K. Lasch8, M. Luo8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, S. Kane2, E.V. Loftus2, B.E. Sands6, W.J. Sandborn3, J.-F. Colombel6, B. Shen5, P.S. Dulai3 1. Indiana University, Indianapolis, United States 2. Mayo Clinic, Rochester, United States 3. University of California - San Diego, La Jolla, United States 4. Montefiore Medical Center, New York, United States 5. Cleveland Clinic Foundation, Cleveland, United States 6. Icahn School of Medicine at Mount Sinai, New York, United States 7. Dartmouth-Hitchcock Medical Center, Lebanon, United States 8. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States 9. New York University (NYU), New York, United States 10. North Shore University Hospital, Manhasset, United States 11. Lenox Hill Hospital, New York, United States 12. University of Mississippi, Jackson, United States |
|
17:00-17:10 |
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysis D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire4, G. Tran4, A. Weiss5, A. Winters1, S. Chablaney1, S. Aniwan6, J.L. Koliani-Pace7, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm4, S. V Sagi4, M. Fischer4, D. Hudesman9, S. Chang9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, W.J. Sandborn3, B.E. Sands1, J.-F. Colombel1, S. Kane6, E.V. Loftus6, P.S. Dulai3 1. Icahn School of Medicine at Mount Sinai, New York, United States 2. Cleveland Clinic Foundation, Cleveland, United States 3. University of California - San Diego, La Jolla, United States 4. Indiana University, Indianapolis, United States 5. Montefiore Medical Center, New York, United States 6. Mayo Clinic, Rochester, United States 7. Dartmouth-Hitchcock Medical Center, Lebanon, United States 8. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States 9. New York University (NYU), New York, United States 10. North Shore University Hospital, Manhasset, United States 11. Lenox Hill Hospital, New York, United States 12. University of Mississippi, Jackson, United States |
OR: |
15:30-17:10 |
Scientific session 9: Basic Science: Evolving concepts of IBD pathogenesis Massimo Fantini, Rome, Italy Britta Siegmund, Berlin, Germany |
|
15:30-15:50 |
Pathogenesis of fistulising IBD Michael Scharl, Zurich, Switzerland |
|
15:50-16:00 |
OP027: SUCNR1 receptor mediates intestinal fibrosis J. Cosin-Roger1, 2, D. Ortiz-Masia2, D.C. Macias-Ceja1, L. Gisbert-Ferrandiz2, P. Salvador2, M. Hausmann3, G. Rogler3, S. Calatayud2, M.D. Barrachina2 1. Fisabio, Hospital Dr Peset, Valencia, Spain 2. University of Valencia, Valencia, Spain 3. University of Zurich, Gastroenterology, Zurich, Switzerland |
|
16:00-16:10 |
OP028: Single cell RNA sequencing of t-cells in Crohn’s Disease identifies tissue specific drug target E. Festen1, R. Weersma1, W.T. Uniken Venema1, M.D. Voskuil1, D. Graham2 1. University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, Netherlands 2. The Broad Institute of MIT and Harvard, Cambridge, United States |
|
16:10-16:30 |
Stress-induced controllers of intestinal inflammatory reactions Hermona Soreq, Jerusalem, Israel |
|
16:30-16:40 |
OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice M. Yabal1, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1 1. Technical University Munich, III. Medizinische Klinik, Munich, Germany 2. Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany 3. Technical University Munich, Institut for Pathologie, Munich, Germany |
|
16:40-16:50 |
OP030: Loss of PTPN2 in dendritic cells promotes T cell activation and expression of co-stimulatory molecules L. Hering1, C. Gottier1, S. Lang1, B. Becher2, G. Rogler1, M. Scharl1, M. Spalinger1 1. University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland 2. University of Zurich, Institute of Experimental Immunologx, Zurich, Switzerland |
|
16:50-17:10 |
How the gut speaks to the liver: Novel insights from PSC pathogenesis Herbert Tilg, Innsbruck, Austria |
17:20-18:20 |
Digital Oral Presentations (Sessions 6-10) |
18:35-19:35 |
Industry sponsored satellite symposia 4a, 4c & 4d |